Recursion.com Acquired for $904,000

2

It looks like George Kirikos may have uncovered another large domain name sale. In a tweet this morning, George reported that Recursion Pharmaceuticals acquired the one word Recursion.com domain name for $904,000:

The acquisition price information was found in the company’s SEC S-1 filing in advance of its IPO. On page F-15 of the S-1 under the “Intangible Asset Acquisitions” heading, the company reported the acquisition:

“Recursion Domain Name

In December 2020, the Company purchased the Recursion domain name for cash consideration of $904. The purchase price was capitalized as an intangible asset with an indefinite useful life.”

As with most corporate filings, the financial figures are in thousands, so “$904” means $904,000 USD. The company doesn’t specifically mention Recursion.com in that section, but Recursion.com is mentioned twice in the S-1 filing.

It is difficult to track the ownership history of this domain name in Whois records due to Whois privacy and GDPR redaction. It looks like it had been owned by a New York company at some point prior to the acquisition.

I added the sale of Recursion.com to the list of recent publicly reported one word .com domain name sales, and I am sure it will be added to DNJournal and NameBio where it will rank amongst the largest public domain name sales of 2020.

2 COMMENTS

    • Well, considering that we’re talking about a pharmaceutical company, I guess the word recursion can be defined as “the process of covertly making you sick with drugs, and then gaining a recurring customer who comes back perpetually with lots of money for your drugs or they’ll die, until you suck out lots of money and they’ll die anyway”. Yep, that’s it.

      So… who wants their experimental mRNA emergency use authorized drug they falsely label as vaccine?

Leave a Reply